Drug Survival of Secukinumab in Real-World Plaque Psoriasis Patients: A 52-Week, Multicenter, Retrospective Study

Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2017.11.036
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Elsevier BV

Related search

Real-World Drug Survival of Ixekizumab for Psoriasis

Journal of the American Academy of Dermatology
Dermatology
2019English

Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque Psoriasis: A Case Report

SAGE Open Medical Case Reports
2020English

Real‐World Evidence of Secukinumab in Psoriasis Treatment – A Meta‐Analysis of 43 Studies

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

Secukinumab: First IL-17A Antagonist for Plaque Psoriasis

Pharmacy Today
2015English

Characteristics of Chronic Plaque Psoriasis in Canada: A Retrospective Database Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Psy29 - Real-World Discontinuation of Biological Treatments in Moderate-To-Severe Plaque Psoriasis Over the First 5 Years of Treatment – A Literature Review of Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy of Secukinumab in Patients With Plaque Psoriasis: Area Under the Curve of Treatment Response Rates

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy